The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic charcot neuroarthropathy

Diabetes

Volumn 60, Issue 8, 2011, Pages 2187-2196

  Ndip, Agbor ^a,b   Williams, Alfred ^b   Jude, Edward B ^b,c   Serracino Inglott, Ferdinand ^a   Richardson, Steve ^a   Smyth, J V ^a   Boulton, Andrew J M ^a,b   Alexander, M Yvonne ^b  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c TAMESIDE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALIZARIN RED S; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PHOSPHATE;

ARTERY CALCIFICATION; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC CHARCOT NEUROARTHROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MINERALIZATION; NEUROPATHIC JOINT DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TIBIAL ARTERY; UPREGULATION;

AGED; CALCINOSIS; CELL DIFFERENTIATION; CELLS, CULTURED; CHARCOT-MARIE-TOOTH DISEASE; DIABETIC NEPHROPATHIES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-8; MALE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION;

EID: 80052829942     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db10-1220     Document Type: Article

References (38)

1. Niskanen L, Siitonen O, Suhonen M, Uusitupa MI. Medial artery calcification predicts cardiovascular mortality in patients with NIDDM. Diabetes Care 1994;17:1252-1256 (Pubitemid 24324967) (Pubitemid 24324967)
2. Lehto S, Niskanen L, Suhonen M, Rönnemaa T, Laakso M. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996;16:978-983
3. Nelson RG, Gohdes DM, Everhart JE, et al. Lower-extremity amputations in NIDDM. 12-yr follow-up study in Pima Indians. Diabetes Care 1988;11: 8-16
4. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938-942 (Pubitemid 34258697) (Pubitemid 34258697)
5. Young MJ, Adams JE, Anderson GF, Boulton AJM, Cavanagh PR. Medial arterial calcification in the feet of diabetic patients and matched nondiabetic control subjects. Diabetologia 1993;36:615-621 (Pubitemid 23186453) (Pubitemid 23186453)
6. Chen NX, Moe SM. Arterial calcification in diabetes. Curr Diab Rep 2003;3: 28-32 (Pubitemid 38906762)
7. Costacou T, Huskey ND, Edmundowicz D, Stolk R, Orchard TJ. Lowerextremity arterial calcification as a correlate of coronary artery calcification. Metabolism 2006;55:1689-1696 (Pubitemid 44827138) (Pubitemid 44827138)
8. Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int 2004;74:103-106 (Pubitemid 38166611) (Pubitemid 38166611)
9. Jeffcoate W. Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link? Diabetologia 2004;47:1488-1492
10. Mabilleau G, Petrova NL, Edmonds ME, Sabokbar A. Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetologia 2008;51:1035-1040
11. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22:549-553 (Pubitemid 34408732) (Pubitemid 34408732)
12. Walsh MC, Choi YW. Biology of the TRANCE axis. Cytokine Growth Factor Rev 2003;14:251-263 (Pubitemid 36693145) (Pubitemid 36693145)
13. Kaden JJ, Bickelhaupt S, Grobholz R, et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 2004;36:57-66 (Pubitemid 38084791) (Pubitemid 38084791)
14. Breuil V, Schmid-Antomarchi H, Schmid-Alliana A, Rezzonico R, Euller- Ziegler L, Rossi B. The receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) is a new chemotactic factor for human monocytes. FASEB J 2003;17:1751-1753
15. Panizo S, Cardus A, Encinas M, et al. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 2009;104:1041-1048
16. Shaw JE, Boulton AJM. The Charcot foot. The Foot 1995;5:65-70
17. Sanders LJ, Frykberg RG. Charcot foot. In The Diabetic Foot. 5th ed. Levin ME, Oneil LW, Bouker JH, Eds. St. Louis, Mosley-Yearbook Inc., 1993, p. 149-180
18. Jude EB, Selby PL, Burgess J, et al. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia 2001;44:2032-2037 (Pubitemid 33124049) (Pubitemid 33124049)
19. Stern A, Laughlin GA, Bergstrom J, Barrett-Connor E. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol 2007;156:555-562 (Pubitemid 46796522) (Pubitemid 46796522)
20. Wilkinson FL, Liu Y, Rucka AK, et al.; Contribution of VCAF-positive cells to neovascularization and calcification in atherosclerotic plaque development. J Pathol 2007;211:362-369 (Pubitemid 46172712) (Pubitemid 46172712)
21. Kirton JP, Wilkinson FL, Canfield AE, Alexander MY. Dexamethasone downregulates calcification-inhibitor molecules and accelerates osteogenic differentiation of vascular pericytes: implications for vascular calcification. Circ Res 2006;98:1264-1272 (Pubitemid 43948081) (Pubitemid 43948081)
22. Petrova NL, Moniz C, Elias DA, Buxton-Thomas M, Bates M, Edmonds ME. Is there a systemic inflammatory response in the acute Charcot foot? Diabetes Care 2007;30:997-998
23. Uccioli L, Sinistro A, Almerighi C, et al. Proinflammatory modulation of the surface and cytokine phenotype of monocytes in patients with acute Charcot foot. Diabetes Care 2010;33:350-355
24. Saidenberg Kermanac'h N, Bessis N, Cohen-Solal M, De Vernejoul MC, Boissier MC. Osteoprotegerin and inflammation. Eur Cytokine Netw 2002; 13:144-153
25. Lam J, Abu-Amer Y, Nelson CA, Fremont DH, Ross FP, Teitelbaum SL. Tumour necrosis factor superfamily cytokines and the pathogenesis of inflammatory osteolysis. Ann Rheum Dis 2002;61(Suppl 2):ii82-ii83
26. Jeffcoate WJ, Game F, Cavanagh PR. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 2005;366:2058-2061 (Pubitemid 41773381) (Pubitemid 41773381)
27. van Tuyl LHD, Voskuyl AE, Boers M, et al. Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Ann Rheum Dis 2010;69: 1623-1628
28. Geusens PP, Landewé RBM, Garnero P, et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006;54:1772-1777 (Pubitemid 43877926)
29. Martini G, Gennari L, Merlotti D, et al. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. Bone 2007;40:457-463 (Pubitemid 46054544) (Pubitemid 46054544)
30. Alvarez L, Peris P, Guañabens N, et al. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis Rheum 2003;48: 824-828 (Pubitemid 36302021) (Pubitemid 36302021)
31. Pino AM, Ríos S, Astudillo P, et al. Concentration of adipogenic and proinflammatory cytokines in the bone marrow supernatant fluid of osteoporotic women. J Bone Miner Res 2010;25:492-498
32. Mezquita-Raya P, de la Higuera M, García DF, et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int 2005;16:1368-1374 (Pubitemid 41532089) (Pubitemid 41532089)
33. Chiba Y, Onouchi T, Ikeda T, Adachi J, Tamura Y, Horiuchi T. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women. Gerontology 2009;55:275-280
34. Nakashima K, Zhou X, Kunkel G, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002;108:17-29 (Pubitemid 34137009) (Pubitemid 34137009)
35. Schoppet M, Al-Fakhri N, Franke FE, et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 2004;89:4104-4112 (Pubitemid 39071519) (Pubitemid 39071519)
36. Novack DV, Yin L, Hagen-Stapleton A, et al. The IkappaB function of NFkappaB2 p100 controls stimulated osteoclastogenesis. J Exp Med 2003; 198:771-781 (Pubitemid 37087776) (Pubitemid 37087776)
37. Chaisson ML, Branstetter DG, Derry JM, et al. Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha. J Biol Chem 2004;279:54841-54848 (Pubitemid 40053230) (Pubitemid 40053230)
38. Tseng W, Graham LS, Geng Y, et al. PKA-induced receptor activator of NF-κB ligand (RANKL) expression in vascular cells mediates osteoclastogenesis but not matrix calcification. J Biol Chem 2010;285:29925-29931